All In Biotech

Drug Trial Radar · NCT05244057

A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients

A Phase II of Randomized, Double-blind, Placebo-controlled, Multi-center Study of Hepalatide for Injection Combined With Pegylated Interferon and TAF as Finite Treatment in Chronic Hepatitis B Patients

Last checked: Nov 19, 2026Latest source record: Jul 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Aug 23, 2022

Primary completion

Jun 24, 2024

Study completion Jun 24, 2024

Sponsor

Sponsor type
Industry
Collaborators
Shanghai Tong Ren Hospital; Shanghai East Hospital
First posted
Feb 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to assess efficacy of a finitie treatment in Chronic Hepatitis B patients who had stable treatment of NAs for ≧ 2 years, which is compared hepalatide in combination with Pegylated Interferon + TAF with Pegylated Interferon +TAF. Subjects will be randomly assigned to the hepalatide or placebo groups , 15 subjects in each group . Subjects will receive hepalatide+Pegylated Interferon +TAF treatment for 48 weeks or placebo +PegylatedInterferon +TAF treatment for 48 weeks , Then, stopping hepalatide and Pegylate Interferon treatments and followed with further 8 weeks follow-up.

Conditions

  • Chronic Hepatitis B

Interventions

  • HepalatideDrug

    6.3mg, s.c., qd for 48 weeks

  • Placebo of HepalatideDrug

    s.c., qd for 48 weeks

  • Tenofovir Alafenamide TabletsDrug

    25mg, p.o., qd for 48 weeks

  • Pegylated Interferon alfa 2aDrug

    90ug, s.c., qw for 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with negative conversion of HBsAgTime frame: 56 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Tong Ren Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.